| 1 |
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah‐Eddin Al‐Batran et al. · The Lancet
|
11 Apr 2019 |
2,700 |
| 2 |
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael G. Pfreundschuh et al. · The Lancet Oncology
|
17 Jan 2008 |
1,139 |
| 3 |
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah‐Eddin Al‐Batran et al. · The Lancet Oncology
|
22 Oct 2016 |
751 |
| 4 |
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton, Karim S. Fizazi, Alison Stopeck et al. · European Journal of Cancer
|
10 Sep 2012 |
592 |
| 5 |
A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
M. D. Green, Heinz Koelbl, José Baselga et al. · Annals of Oncology
Open access |
17 Dec 2002 |
588 |
| 6 |
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
Michael Untch et al. · The Lancet Oncology
|
8 Feb 2016 |
422 |
| 7 |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
Jean‐Jacques Body, Ingo Diel, Michail R Lichinitser et al. · Annals of Oncology
Open access |
Sep 2003 |
416 |
| 8 |
Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein
Matthias Baumann et al. · Journal of Neurology Neurosurgery & Psychiatry
|
13 Aug 2014 |
314 |
| 9 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Salah Eddin Al-Batran, Joerg Thomas Hartmann, Ralf‐Dieter Hofheinz et al. · Annals of Oncology
Open access |
Aug 2008 |
281 |
| 10 |
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Viola Poeschel et al. · The Lancet
Open access |
Dec 2019 |
257 |
| 11 |
Antimicrobial therapy of unexplained fever in neutropenic patients
Hartmut Link, A. B�hme, Oliver A. Cornely et al. · Annals of Hematology
|
Oct 2003 |
251 |
| 12 |
Blunted Cortisol Responses to Psychosocial Stress in Asthmatic Children: A General Feature of Atopic Disease?
Angelika Buske-Kirschbaum, Kristin von Auer, Silke Krieger et al. · Psychosomatic Medicine
|
Sep 2003 |
222 |
| 13 |
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Waßmann, Heike Pfeifer, Michael Beda Stadler et al. · Blood
Open access |
7 Apr 2005 |
204 |
| 14 |
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Anneliese Nitz et al. · Breast Cancer Research and Treatment
Open access |
29 Jun 2017 |
190 |
| 15 |
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Karolin Behringer et al. · The Lancet
|
21 Dec 2014 |
184 |
| 16 |
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
Ursula Nestle et al. · The Lancet Oncology
|
12 Mar 2020 |
182 |
| 17 |
Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Werner Heinz, Dieter Buchheidt, Maximilian Christopeit et al. · Annals of Hematology
Open access |
30 Aug 2017 |
177 |
| 18 |
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Thierry André, Jose M. Reyes-Vidal, Lætitia Fartoux et al. · British Journal of Cancer
Open access |
26 Aug 2008 |
176 |
| 19 |
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas
María A. Tichomirowa et al. · European Journal of Endocrinology
Open access |
14 Jul 2011 |
174 |
| 20 |
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann et al. · European Journal of Cancer
|
11 Oct 2012 |
168 |
| 21 |
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Ingo Diel, Jean‐Jacques Body, Michail R Lichinitser et al. · European Journal of Cancer
|
30 May 2004 |
165 |
| 22 |
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
Ulrike Anneliese Nitz et al. · Journal of Clinical Oncology
|
20 Feb 2019 |
148 |
| 23 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz et al. · JNCI Journal of the National Cancer Institute
|
13 Nov 2017 |
135 |
| 24 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
Eric Van Cutsem, Corrado Boni, Josep M. Tabernero et al. · Annals of Oncology
Open access |
22 Nov 2014 |
133 |
| 25 |
Vertebral body stenting: a new method for vertebral augmentation versus kyphoplasty
Robert Rotter, Heiner Martin, Sebastian Fuerderer et al. · European Spine Journal
Open access |
28 Feb 2010 |
129 |
| 26 |
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
Sibylle Loibl et al. · Annals of Oncology
Open access |
3 Nov 2016 |
120 |
| 27 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
Stefan Hubert Boeck, Andreas Jung, Rüdiger Paul Laubender et al. · British Journal of Cancer
Open access |
20 Nov 2012 |
117 |
| 28 |
Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer
Chris Manegold, Bengt Bergman, Assaad Chemaissani et al. · Annals of Oncology
Open access |
Jun 1997 |
114 |
| 29 |
Wholesome Nutrition: an example for a sustainable diet
Karl von Koerber, Nadine Bader, Claus Leitzmann · Proceedings of The Nutrition Society
Open access |
9 Aug 2016 |
113 |
| 30 |
Acute exposure to nocturnal train noise induces endothelial dysfunction and pro-thromboinflammatory changes of the plasma proteome in healthy subjects
Johannes Herzog, Frank Patrick Schmidt, Omar Hahad et al. · Basic Research in Cardiology
Open access |
29 Oct 2019 |
107 |
| 31 |
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
Ralf‐Dieter Hofheinz et al. · Journal of Clinical Oncology
|
16 Jun 2022 |
100 |
| 32 |
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Rüdiger Hehlmann et al. · Leukemia
Open access254 authors |
7 May 2020 |
93 |
| 33 |
Hypothalamic-Pituitary-Adrenal Axis Function and the Cellular Immune Response in Former Preterm Children
Angelika Buske-Kirschbaum, Silke Krieger, Chloe Wilkes et al. · The Journal of Clinical Endocrinology & Metabolism
|
14 Jun 2007 |
90 |
| 34 |
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
C.-H. Köhne, Raphael Catane, B. Klein et al. · British Journal of Cancer
Open access |
Sep 2003 |
89 |
| 35 |
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
Manuel Barreto Miranda et al. · Leukemia
Open access |
9 Feb 2016 |
88 |
| 36 |
Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism
Lukas Hobohm, Ingo Sagoschen, Andreas Habertheuer et al. · Resuscitation
Open access |
13 Oct 2021 |
87 |
| 37 |
The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial
Mark Coburn et al. · British Journal of Anaesthesia
Open access |
16 Dec 2017 |
80 |
| 38 |
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Michael Clemens, Oleg A. Gladkov, Elaina M. Gartner et al. · Breast Cancer Research and Treatment
Open access |
29 Dec 2014 |
80 |
| 39 |
Effect of dietary phytochemicals on cancer development (review)
Ali Reza Waladkhani, Michael Clemens · International Journal of Molecular Medicine
|
Apr 1998 |
80 |
| 40 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
Stefan Hubert Boeck, Thomas Hoehler, Gernot Seipelt et al. · Annals of Oncology
Open access |
25 Oct 2007 |
78 |
| 41 |
Use of routine thoracic and abdominal computed tomography scans for assessing bone mineral density and detecting osteoporosis
Milka Marinova, Bob Edon, Karsten Wolter et al. · Current Medical Research and Opinion
|
26 Aug 2015 |
78 |
| 42 |
Overweight and basal metabolic rate in boys with attention-deficit/hyperactivity disorder
Ralph Hubel, Jana Jaß, Alexander M. Marcus et al. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
|
Sep 2006 |
75 |
| 43 |
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
Willem W ten Bokkel Huinink, Bengt Bergman, Assad Chemaissani et al. · Lung Cancer
|
Nov 1999 |
73 |
| 44 |
A multicentre randomised controlled trial of the McGrath ™ Mac videolaryngoscope versus conventional laryngoscopy
Marc Kriege, Ruediger R. Noppens, Timothy P. Turkstra et al. · Anaesthesia
Open access |
16 Mar 2023 |
72 |
| 45 |
Increased responsiveness of the hypothalamus–pituitary–adrenal (HPA) axis to stress in newborns with atopic disposition
Angelika Buske-Kirschbaum, Sonja Fischbach, Wolfgang Rauh et al. · Psychoneuroendocrinology
|
25 Nov 2003 |
71 |
| 46 |
Balancing restrictions and access to maternity care for women and birthing partners during the COVID‐19 pandemic: the psychosocial impact of suboptimal care
Joan Lalor, Susan Ayers, Joseph Agius et al. · BJOG An International Journal of Obstetrics & Gynaecology
Open access |
16 Jul 2021 |
67 |
| 47 |
Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia – The case in favour
Wolfgang Thomas, Christian Paul Speer · Paediatric Respiratory Reviews
|
13 Oct 2013 |
65 |
| 48 |
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Peyman Hadji, M. Ziller, Dirk Guenter Kieback et al. · Annals of Oncology
Open access |
14 Feb 2009 |
63 |
| 49 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)
Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Sibylle Loibl et al. · Breast Cancer Research and Treatment
|
11 Jun 2011 |
61 |
| 50 |
Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer
Matthias Christgen et al. · Cancer
Open access |
11 Aug 2020 |
57 |